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Abstract A small GTPase, Rho, participates in agonist-induced
cytoskeletal organization and gene expression in many cell types
including cardiac myocytes. However, little is known about the
functions of Rho’s downstream targets in cardiac myocytes. We
examined the role of ROCK, a downstream target of Rho, in ET-
1-induced hypertrophic response. Y27632, a selective ROCK
inhibitor, inhibited ET-1-induced increases in natriuretic peptide
production, cell size, protein synthesis, and myofibrillar organi-
zation. In addition, a dominant-negative mutant of p160ROCK
suppressed ET-1-induced transcription of the BNP gene. These
findings suggest that the Rho/ROCK pathway is an important
component of ET-1-induced hypertrophic signals in cardiac
myocytes.
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1. Introduction
There is increasing evidence that the vasoactive peptide,
endothelin-1 (ET-1), plays an important role in the develop-
ment of cardiac hypertrophy or heart failure [1^3]. In cultured
neonatal rat cardiac myocytes, ET-1 induces a hypertrophic
response [4^7] ; they are characterized by induction of early
immediate genes, reactivation of the fetal gene program, in-
creases in protein synthesis and cell size, and cytoskeletal re-
organization, and they serve as a well-de¢ned model of car-
diac hypertrophy [8]. ET-1 activates multiple signaling
pathways in cultured cardiac myocytes [9^11]. However, the
precise signaling mechanisms responsible for induction of the
hypertrophic response have not yet been fully elucidated.
A small GTPase, Rho, is known to regulate the organiza-
tion of the actin cytoskeleton and control formation of stress
¢bers and focal adhesions [12,13]. In addition to its cytoskel-
etal e¡ects, Rho is involved in c-fos expression through the
serum response element (SRE) located in the promoter region
[14,15]. Rho is activated by a variety of growth factors in
several systems; these include the G protein-coupled receptor
agonists LPA, bombesin, norepinephrine and ET-1 [16^20].
Furthermore, recent reports implicate Rho in the angiotensin
II (AII)- and phenylephrine-induced myo¢brinogenesis asso-
ciated with the hypertrophic process in cardiac myocytes[21^
23]. It is not known, however, whether Rho mediates ET-1-
evoked hypertrophic signals in cardiac myocytes.
Several downstream targets of Rho have recently been iden-
ti¢ed; these include PKN, p160ROCK (ROCK-I), ROKK
(ROCK-II and Rho-kinase), and citron [13]. Among these,
p160ROCK and ROKK are two isoforms of Rho-associated
coiled-coil forming serine/threonine kinase and exhibit 90%
identity in their kinase domains. They are involved in Rho-
mediated stress ¢ber formation and induction of focal adhe-
sions in cultured cells [16,24,25], and are expressed in the
heart [26]. Thus, the Rho/ROCK pathway may mediate hy-
pertrophic signals in cardiac myocytes. To address this ques-
tion, we examined the involvement of the Rho/ROCK path-
way in the ET-1-induced hypertrophic response in cultured
cardiac myocytes using a selective ROCK inhibitor, Y27632
[27], and a dominant-negative mutant of p160ROCK [24]. Our
results indicate that the Rho/ROCK pathway may be an im-
portant component of ET-1-induced hypertrophic signals in
cardiac myocytes.
2. Materials and methods
2.1. Chemicals and antibodies
Human ET-1 was purchased from Peptide Institute, Inc. Y27632
was a gift from Yoshitomi Pharmaceutical Industries, Ltd. C3 exoen-
zyme and KD-IA, a dominant-negative mutant of p160ROCK, were
gifts from Dr. Shuh Narumiya (Kyoto University).
2.2. Plasmid construction
To investigate the regulatory mechanism of ANP and BNP gene
transcription by ET-1, we prepared two promoter/luciferase reporter
constructs: 312969hANP/Luc and 35875 hBNP/Luc. To generate
312969hANP/Luc, the original clone pUCHBNP [28] containing a
V3.3 kbp fragment of the human brain natriuretic peptide (hBNP)
gene was digested with HindIII. The fragment consisting of the hBNP
gene from 31812 to +1472 was isolated and ligated into the HindIII
site of pBS sk3 (pBSHBNP). The original clone containing an V11
kbp human genomic DNA fragment from the third exon of the BNP
gene to the second exon of the ANP gene [29], which are located in
tandem about 10 kbp apart, was digested with KpnI/SacI, HindIII/
EcoRV and EcoRV/EcoRI. The isolated KpnI/SacI fragments contain-
ing the hANP gene from 3332 to the initiator ATG were inserted into
the KpnI/SacI site of PGV-B2 (Toyo Inc. Co., Ltd.) and designated
3332hANP/Luc; the HindIII/EcoRV and EcoRV/EcoR I fragments
were inserted into pBSHBNP (pBSHB-ANP). pBSHB-ANP contained
the 12 969 bp of the ANP 5P-£anking sequence (FS). pBSHB-ANP
was digested with KpnI, and the fragment consisting of the 5P-FS of
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the hANP gene from 312 969 to 3332 was inserted into the KpnI site
of the 3332hANP/Luc gene and designated 312969hANP/Luc.
To generate 35875hBNP/Luc, the fragments consisting of the
hBNP gene from 35875 to the initiator ATG were isolated from
the original clone P1-hBNP, which was cloned from a human genomic
library using hBNP cDNA as a probe, by digestion with BamHI, and
inserted into the BglII site of PGV-B2. The direction of the inserted
fragments was con¢rmed by sequencing.
Mutations in the SRE of the ANP gene were generated by polymer-
ase chain reaction (PCR) using wild type 3332hANP/Luc and its
homologous SRE mutant as templates; an upstream sense oligo-
nucleotide (ATAGGTACCAGCGTCGAGGAGAAAGAA), which
incorporates the KpnI site at the 5P end, and a downstream anti-
sense oligonucleotide (TAAGAGCTCATGCTGGCGTCGTCAAG-
G), which incorporates the SacI site at the 3P end, were used to
amplify the relevant fragments, which were then cloned into the
KpnI/SacI sites of PGV-B2. The PCR-generated fragments were se-
quenced.
2.3. Cell culture and transfection
Neonatal rat ventricular myocytes were prepared on a Percoll gra-
dient as previously described [5]. Transient transfection into cardiac
myocytes was carried out by electroporation at 280 V and 300 mF as
previously reported [29]. 10 Wg of hANP/Luc or hBNP/Luc reporter
construct was transfected per 3U106 cells. In addition, 4 Wg of pRL-
TK (Toyo Inc. Co., Ltd.) in which herpes simplex virus thymidine
kinase promoter was fused to the Renilla luciferase gene was co-trans-
fected and used to normalize luciferase activity. Cells stimulated for
48 h were harvested, lysed and assayed for luciferase with a lumin-
ometer (Lumat LB 9567; Laboratorium of Prof. Dr. Berthold GmbH
and Co.) according to the manufacturer’s protocol (Toyo Inc. Co.,
Ltd.). Aliquots of cell lysate from quadruplicate wells were assayed
and averaged in each experiment. hANP/Luc or hBNP/Luc luciferase
activity was normalized to pRL-TK luciferase activity (relative lucif-
erase activity); the relative luciferase activity of the constructs incu-
bated with vehicle was arbitrarily assigned a value of 1. At least three
independent cultures were performed.
2.4. Radioimmunoassay of ANP and BNP
The concentrations of ANP and BNP were measured using our
speci¢c radioimmunoassays (RIAs) as previously reported [5].
2.5. Analysis for protein synthesis
New protein synthesis in cultured cells was evaluated as a function
of [3H]leucine incorporation. The cells were cultured in the presence
or absence of various agents for 48 h. [3H]Leucine (3 WCi; Amersham
Life Science) was then added, and the cells were incubated for an
additional 24 h. Cell precipitates were solubilized in 0.2 N NaOH
for more than 4 h, and radioactivity was determined by liquid scin-
tillation spectrometry.
2.6. Immuno£uorescent staining
Cultured cardiac myocytes were ¢xed in 3.7% formaldehyde for
10 min. Actin ¢bers were stained with 1 Wg/ml of FITC-conjugated
phalloidin (Sigma) as described previously [21,31]. Cells were observed
using a laser scanning microscope.
2.7. Analysis of cultured cell size
Phase-contrast microphotographs were ¢rst scanned using a digital
image analysis system. The size of cardiac myocytes was estimated by
measuring their areas of attachment to the culture plates.
2.8. Statistical analysis
Data are presented as means þ S.E.M. Analysis of variance
(ANOVA) with post hoc Fisher’s test was used to determine signi¢-
cant di¡erences. Values of P6 0.05 were considered signi¢cant.
3. Results
3.1. Inhibition of Rho or ROCK blocked ET-1-induced
secretion of natriuretic peptides
To determine the role of Rho in ET-1-induced hypertrophic
responses, we evaluated the e¡ect of the Rho inhibitor, C3, on
ET-1-induced increases in ANP/BNP secretion. As shown in
Fig. 1A, C3 dose-dependently inhibited ET-1-induced secre-
tion of both ANP and BNP. The concentrations of C3 (60
and 30 Wg/ml) were selected in the context of earlier reports
showing that pretreatment with 80 Wg/ml C3 decreased the
amount of Rho available for the back-ribosylation reaction
by 80% [22], and 100 Wg/ml completely inhibited AII-induced
ANP gene expression [21].
Next we examined whether ROCK, a downstream target of
Rho, mediates ET-1-induced ANP/BNP secretion, by treating
myocytes with Y27632, a selective inhibitor of ROCK [27].
The compound Y27632 is a novel pyridine derivative that
suppresses Rho- and ROCK-induced stress ¢ber assembly
but has no e¡ect on Rac-induced membrane ru¥ing or
Cdc42-induced ¢lopodia formation [27]. As shown in Fig.
1B, Y27632 signi¢cantly inhibited ET-1-induced ANP/BNP
secretion from cardiac myocytes. These results suggest that
the Rho/ROCK pathway is involved in the ET-1-induced sig-
nals leading to ANP/BNP secretion.
Fig. 1. ANP and BNP concentrations in cultured media. A: Cells
were pretreated with the indicated concentration of C3 for 6 h prior
to the addition of 1 nM ET-1 for 24 h (left panel) or 48 h (right
panel). Values obtained from two independent cultures in triplicate
are shown as means þ S.E.M.; *P6 0.05 vs. ET-1 without C3;
2P6 0.05 vs. vehicle without C3. B: Cells were preincubated for 1 h
with the indicated concentration of Y27632 prior to the addition of
1 nM ET-1 for 24 h (left panel) or 48 h (right panel). Values ob-
tained from three independent cultures in quadruplicate wells are
shown as means þ S.E.M.; *P6 0.05 vs. ET-1 without Y27632;
2P6 0.05 vs. vehicle without Y27632.
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3.2. Y27632 inhibits ET-1-induced natriuretic peptide gene
expression
To assess the participation of ROCK in the regulation of
ANP/BNP gene transcription, reporter genes containing the
5P-FS of the ANP or BNP gene (Fig. 2A) were transfected
into cardiac myocytes, and the e¡ect of ROCK inhibition on
ET-1-induced reporter activity was evaluated. Y27632 signi¢-
cantly inhibited ET-1-induced reporter activity (Fig. 2B,C).
Furthermore, transient transfections with KD-IA, a domi-
nant-negative mutant of p160ROCK, inhibited ET-1-induced
35875hBNP/Luc expression in a dose-dependent manner
(Fig. 2D). All these results show the involvement of ROCK
in the pathways leading to transcription of the natriuretic
peptide genes.
Rho is reported to activate serum response factor thereby
upregulating c-fos transcription via SRE elements [14,15].
With respect to the ANP gene expression, the SRE element
located in the proximal ANP 5P-FS is reported to mediate
hypertrophic signals [30]. We therefore examined the extent
to which ROCK was involved in the induction of ANP gene
transcription via activation of the SRE element. To accom-
plish this, we generated a reporter gene containing a mutated
SRE element within the proximal promoter of the ANP gene,
and then evaluated the e¡ect of Y27632 on ET-1-induced
Fig. 2. A: Schematic representation of the structure of the reporter construct. Band C, 312969hANP/Luc (B) and 35875hBNP/Luc (C) gene
expression. Transfected cells were incubated with 1 nM ET-1 in the presence or absence of 10 WM Y27632 for 48 h. Values are shown as
means þ S.E.M.; *P6 0.05 vs. control; 2P6 0.05 vs. ET-1 without Y27632. D: 10 Wg of 35875hBNP/Luc and 4 Wg of pRL-TK with varying
concentrations of KD-IA as indicated were transiently transfected into cardiac myocytes. DNA concentration for all samples was adjusted to
34 Wg with inert DNA (pCAG-myc). The relative luciferase activities of reporter genes transfected without KD-IA and treated with vehicle
were arbitrarily assigned a value of 1. Values are shown as means þ S.E.M.; *P6 0.05 vs. 35875hBNP/Luc transfected without KD-IA and
treated with ET-1. E: The promoter sequence and the mutated bases (top) are shown. The mutation was prepared in the 3332ANP/Luc.
F: Expression of 3323hANP/Luc genes in cardiac myocytes with or without SRE mutation. Transfected cardiac myocytes were incubated with
1 nM ET-1 in the presence or absence of 10 WM Y27632 for 48 h. Values are mean þ S.E.M.; *P6 0.05 vs. control; 2P6 0.05 vs. ET-1 without
Y27632.
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ANP gene expression(Fig. 2E,F). We observed that the inhib-
itory e¡ect of Y27632 was una¡ected by the mutation, sug-
gesting that the ANP gene transcription mediated via ROCK
is independent of SRE activation.
We also examined whether Y27632 attenuated other ET-1-
induced signaling pathways, p44/42 MAPK and p38 MAPK
pathways. Y27632 did not a¡ect ET-1-induced activities of
p44/42 MAPK and p38 MAPK signi¢cantly (data are not
shown), indicating that the Rho/ROCK pathway and
MAPK pathways are independently regulated. The results
are consistent with the previous report by Sah et al. [22],
showing that the Rho and MAPK pathways independently
mediate PE-induced hypertrophic signals.
3.3. Y27632 inhibits ET-1-induced increases in protein
synthesis, cell size and myo¢brillar organization
We next examined whether ROCK was involved in other
hypertrophic responses induced by ET-1: an increase in my-
ocyte cell size, protein synthesis and myo¢brillar organization.
Y27632 attenuated ET-1-induced increases in protein synthe-
sis (Fig. 3A) and size of cardiac myocytes (Table 1). In addi-
tion, striated sarcomeric actin ¢bers appeared thinner and less
dense in cells treated with Y27632 (Fig. 3B^D), suggesting
that the Rho/ROCK pathway is signi¢cantly involved in
the myo¢brillar reorganization induced by hypertrophic stim-
uli.
4. Discussion
In this study we evaluated the participation of the Rho/
ROCK pathway in ET-1-induced hypertrophic signals in car-
diac myocytes. To examine roles of ROCK, we used Y27632,
a recently reported speci¢c inhibitor of ROCK [27], because
Y27632 is used in a growing number of reports to determine
the roles of ROCK [31^39]. Y27632 signi¢cantly suppressed
ET-1-induced hypertrophic responses: augmentation of na-
triuretic peptide gene expression, increase in protein synthesis
and cell size, and myo¢brillar reorganization. In addition,
KD-IA, a dominant-negative mutant of p160ROCK, inhibited
ET-1-induced hBNP promoter activation, as Y27632 did.
These results suggest that the Rho/ROCK pathway is an im-
portant mediator of ET-1-induced hypertrophic signals in car-
diac myocytes.
The downstream targets of ROCK in the hypertrophic sig-
nals are not yet known. Rho is reported to be involved in
agonist-induced c-fos expression in ¢broblasts, which is medi-
ated by SRE in the c-fos promoter [14,15]. However, the mu-
tation in the proximal SRE in the ANP promoter did not
attenuate the inhibitory e¡ect of Y27632, suggesting that
ROCK-mediated ANP gene expression appeared to be SRE-
independent. This ¢nding is consistent with the recent sugges-
tion by Sahai et al. that ROCK is not required for activation
for serum response factor [40]. However, other downstream
targets of Rho (e.g. PKN) may mediate hypertrophic signals
via SRE.
In conclusion, we showed that the Rho/ROCK pathway is
an important mediator of ET-1-induced hypertrophic signals
in cultured cardiac myocytes. Further studies are required to
determine roles of this pathway in in vivo cardiac hypertro-
phy.
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Fig. 3. A: The radioactivity of the incorporated [3H]leucine in cells
pretreated with 10 WM Y27632 for 1 h prior to the addition of
1 nM ET-1 was assayed as described in Section 2. The radioactivity
in cells treated with a vehicle as a control was arbitrarily assigned a
value of 100(%). Values obtained from two independent cultures in
quadruplicate are shown as means þ S.E.M.; *P6 0.05 vs. control;
2P6 0.05 vs. ET-1 without Y27632. B^D: The e¡ect of Y27632 on
ET-1-induced sarcomeric actin organization. Cardiac myocytes
grown on a gelatin-coated slide glass were incubated with a vehicle
(B) or 1 nM ET-1 (C,D) in the presence (D) or absence (B,C) of
10 WM Y27632 for 48 h. Cells were stained with FITC-phalloidin.
Bar represents 20 Wm (D).
Table 1
Cell size of cultured ventricular myocytes
MC size (Wm2)
Control 367 þ 40
Control+Y27632 262 þ 29
ET-1 644 þ 53*
ET-1+Y27632 406 þ 362
Cultured ventricular myocytes were preincubated with or without
10 WM Y27632 for 1 h prior to the addition of either a vehicle or
1 nM ET-1 for 48 h. The area of cell attachment was measured by
digital image analysis. Values are means þ S.E.M. (Wm2) (sizes of
40 cells for each group were measured).
*P6 0.05 vs. vehicle without Y27632.
2
P6 0.05 vs. ET-1 without Y27632.
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